G

ood morning, everyone, and welcome to the middle of the week. There’s just a few more days until the rush of meetings and deadlines and paperwork can be put aside for a bit of late-summer relaxation. So, in the meantime, keep plugging away. I’m Rebecca Robbins, and I’m a reporter for STAT, filling in again to bring you a menu of headlines from the world of pharma. Shall we get started?

Teva (TEVA) is looking for partners to help fund development of some of the drug compounds in its pipeline, Reuters informs us. The generic drug giant aims to reduce its debt load by more than $5 billion this year.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy